Equities research analysts expect Thermo Fisher Scientific Inc. (NYSE:TMO) to report sales of $6.02 billion for the current quarter, according to Zacks. Six analysts have provided estimates for Thermo Fisher Scientific’s earnings, with the highest sales estimate coming in at $6.06 billion and the lowest estimate coming in at $5.97 billion. Thermo Fisher Scientific posted sales of $5.85 billion in the same quarter last year, which would indicate a positive year over year growth rate of 2.9%. The firm is scheduled to report its next earnings report on Wednesday, April 24th.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full year sales of $25.21 billion for the current fiscal year, with estimates ranging from $25.10 billion to $25.34 billion. For the next financial year, analysts forecast that the business will report sales of $26.56 billion, with estimates ranging from $26.22 billion to $27.07 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 earnings per share for the quarter, beating the consensus estimate of $3.19 by $0.06. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.26 billion. During the same period last year, the business earned $2.79 EPS. The business’s revenue was up 7.6% on a year-over-year basis.
Several equities analysts have weighed in on TMO shares. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $270.00 price objective on the stock in a research note on Monday, November 19th. Needham & Company LLC started coverage on Thermo Fisher Scientific in a research note on Wednesday, January 2nd. They set a “strong-buy” rating and a $271.00 price objective on the stock. Finally, Barclays raised their price objective on Thermo Fisher Scientific from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, January 3rd. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $275.70.
In other news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 4th. The stock was sold at an average price of $266.00, for a total transaction of $665,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gregory J. Herrema sold 3,299 shares of Thermo Fisher Scientific stock in a transaction on Friday, March 1st. The stock was sold at an average price of $263.05, for a total value of $867,801.95. The disclosure for this sale can be found here. Insiders have sold a total of 36,927 shares of company stock worth $9,388,124 over the last quarter. Company insiders own 0.49% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMO. Capital Financial Planning LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth about $27,000. Hanson McClain Inc. increased its holdings in Thermo Fisher Scientific by 263.9% in the 4th quarter. Hanson McClain Inc. now owns 131 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares during the last quarter. Capital Investment Advisory Services LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth about $35,000. Gradient Investments LLC increased its holdings in Thermo Fisher Scientific by 1,887.5% in the 4th quarter. Gradient Investments LLC now owns 159 shares of the medical research company’s stock worth $36,000 after acquiring an additional 151 shares during the last quarter. Finally, WESPAC Advisors SoCal LLC increased its holdings in Thermo Fisher Scientific by 70.0% in the 4th quarter. WESPAC Advisors SoCal LLC now owns 170 shares of the medical research company’s stock worth $38,000 after acquiring an additional 70 shares during the last quarter. Institutional investors own 87.11% of the company’s stock.
NYSE:TMO traded up $1.66 during trading hours on Friday, hitting $263.09. 2,371,785 shares of the company traded hands, compared to its average volume of 1,748,235. The company has a current ratio of 1.73, a quick ratio of 1.23 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a one year low of $199.85 and a one year high of $266.18. The stock has a market cap of $104.31 billion, a PE ratio of 23.66, a price-to-earnings-growth ratio of 1.68 and a beta of 1.13.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 16th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.29%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 6.12%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.